Amended Current Report Filing (8-k/a)
June 24 2022 - 6:02AM
Edgar (US Regulatory)
0001728328
true
A1
0001728328
2022-06-23
2022-06-23
0001728328
dei:FormerAddressMember
2022-06-23
2022-06-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 23, 2022
INMED
PHARMACEUTICALS INC.
(Exact Name of Company as Specified in Charter)
British Columbia |
|
001-39685 |
|
98-1428279 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
InMed Pharmaceuticals Inc. |
|
|
Suite 310 - 815 W. Hastings Street, |
|
|
Vancouver, B.C. |
|
|
Canada |
|
V6C 1B4 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Company’s telephone number, including
area code: (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Shares, no par value |
|
INM |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Explanatory Note
On June 22, 2022, InMed Pharmaceuticals Inc. (the
“Company”) filed a Form 8-K (the “Original Form 8-K”). This Amendment to Form 8-K is being filed to correct a
typographical error in the Original Form 8-K. In connection with such clarification, the corrected content under Item 3.01 is stated herein.
Except as set forth herein, the remainder of the Original Form 8-K remains unchanged.
Item 3.01 Notice of Delisting or Failure to
Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
The below sentence amends and restates the original
first sentence under Item 3.01 in its entirety.
“On June 17, 2022,
the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market (“Nasdaq”),
notifying it that based upon the closing bid price of the Company’s common shares for the last 30 consecutive business days, the
Company no longer meets the minimum bid price of $1 per share, as required under Nasdaq Listing Rule 5550(a)(2).”
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INMED PHARMACEUTICALS INC. |
|
|
|
Date: June 23, 2022 |
By: |
/s/ Brenda Edwards |
|
|
Brenda Edwards |
|
|
Interim Chief Financial Officer |
2
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024